

Abstract

The invention relates to modified recombinant allergen mutants which can be obtained from recombinant allergens which are derived from allergens which can be obtained by extraction from natural raw materials such as pollen of the species *Phleum pratense*. While these modified recombinant allergens stimulate lymphocytes from patients who are allergic to pollen to proliferate and synthesize cytokines, they exhibit a markedly diminished ability to bind to the IgE antibodies which are present in the serum of the T lymphocyte donors and to grass pollen allergen-specific IgEs and can therefore be used for a specific, made-to-measure allergy therapy.